Damoctocog alfa pegol

N/A

Report date: 2022/05/11 12:44:49

Base Information

Drug NameDamoctocog alfa pegol
Drug Alias Namedamoctocogum alfa pegolum培戈-丹凝血素-8αantihemophilic factor (recombinant), PEGylated-aucl培达凝血素αPEGylated B-Domain-Delted Recombinant rFVIII +[13] 
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant coagulation factor
Mechanisms of ActionCoagulation factor VIII replacementsCoagulation factor X stimulantsBlood coagulation pathway activation
TargetsCoagulation factor X
Therapy Area/IndicationsHemorrhageHemophilia A
Global Approved IndicationsHemophilia A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2018/08/29
Country/TerritoryBelgiumBulgariaCanada +[28] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBayer AG
China Registration ClassN/A

Develop Information

Active CompaniesBayer HealthcareBayer AG
Inactive CompaniesN/A
Active IndicationsHemorrhageHemophilia A
Inactive IndicationsN/A

Other Information

ATC CodeB02BD02
Related LinksKEGG